|
US2019048341A1
|
|
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
CA2997949A1
|
|
Methods for treating skin disorders and conditions utilizing haptens
|
|
WO2017007825A1
|
|
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
KR20180026739A
|
|
A nucleic acid molecule targeting superoxide dismutase 1 (SOD1)
|
|
CA2969590A1
|
|
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
KR20170044749A
|
|
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
|
WO2015168605A1
|
|
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
CA2947270A1
|
|
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
WO2015085113A1
|
|
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
EP3079707A2
|
|
Immunotherapy of cancer
|
|
CA2794187A1
|
|
Rna interference in ocular indications
|
|
WO2011119852A1
|
|
Reduced size self-delivering rnai compounds
|
|
WO2011109698A1
|
|
Formulations and methods for targeted delivery to phagocyte cells
|
|
EP2542058A1
|
|
Effective sensitizing dose of a gelled immunomodulating topical composition
|
|
WO2010090762A1
|
|
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
WO2010078536A1
|
|
Inhibition of pcsk9 through rnai
|
|
CN102405286A
|
|
Reduced size self-delivering rnai compounds
|
|
WO2010011346A1
|
|
Rnai constructs and uses therof
|
|
WO2010008582A2
|
|
Phagocytic cell delivery of rnai
|
|
AU2009213147A1
|
|
Modified RNAi polynucleotides and uses thereof
|
